QLT 091568

Drug Profile

QLT 091568

Alternative Names: OT-730

Latest Information Update: 30 Nov 2016

Price : $50

At a glance

  • Originator Othera Pharmaceuticals
  • Class Antiglaucomas; Antihypertensives; Small molecules
  • Mechanism of Action Beta-adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glaucoma; Ocular hypertension

Most Recent Events

  • 29 Nov 2016 QLT acquired Aegerion Pharmaceuticals and later QLT changed its name to Novelion Therapeutics
  • 03 Nov 2010 Discontinued - Phase-I/II for Glaucoma in USA (Ophthalmic)
  • 30 Dec 2009 QLT acquires OT 730 from Othera Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top